TY - JOUR
T1 - Surfactant protein A activates NF-κB in the THP-1 monocytic cell line
AU - Koptides, Michael
AU - Umstead, Todd M.
AU - Floros, Joanna
AU - Phelps, David S.
PY - 1997
Y1 - 1997
N2 - The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-κB. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-κB. We used gel shift assays to determine whether SP-A activated NF-κB in the THP-1 cell line, a human monocytic cell line. Activation of NF-κB in THP-1 cells by SP-A doses as low as 1 μg/ml occurred within 30 min of SPA treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-κB or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-κB inhibitors blocked SP-A-dependent increases in tumor necrosis factor-α mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung.
AB - The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-κB. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-κB. We used gel shift assays to determine whether SP-A activated NF-κB in the THP-1 cell line, a human monocytic cell line. Activation of NF-κB in THP-1 cells by SP-A doses as low as 1 μg/ml occurred within 30 min of SPA treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-κB or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-κB inhibitors blocked SP-A-dependent increases in tumor necrosis factor-α mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung.
UR - http://www.scopus.com/inward/record.url?scp=0030805245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030805245&partnerID=8YFLogxK
U2 - 10.1152/ajplung.1997.273.2.l382
DO - 10.1152/ajplung.1997.273.2.l382
M3 - Article
C2 - 9277450
AN - SCOPUS:0030805245
SN - 1040-0605
VL - 273
SP - L382-L388
JO - American Journal of Physiology - Lung Cellular and Molecular Physiology
JF - American Journal of Physiology - Lung Cellular and Molecular Physiology
IS - 2 17-2
ER -